Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff-by-the-Sea, California.
IPO Year: 2005
Exchange: NASDAQ
Website: viracta.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2024 | $5.00 → $3.00 | Outperform → Market Perform | Leerink Partners |
| 2/1/2022 | $10.00 | Outperform | RBC Capital Mkts |
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
10-Q - Viracta Therapeutics, Inc. (0001061027) (Filer)
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
10-Q - Viracta Therapeutics, Inc. (0001061027) (Filer)
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
- Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data from expansion phase of the Phase 2 NAVAL-1 clinical trial of Nana-val in the first half of 2025 - - Determined recommended Phase 2 dose of Nana-val in patients with advanced EBV-positive solid tumors - SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial
SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that the company has implemented a reprioritization of resources intended to enhance the company's focus on its Nana-val development program in patients with relapsed or refractory (R/R) EBV-positive peripheral T-cell lymphoma (PTCL). To further align resources with current pipeline priorities, Viracta is announcing today that it has implemented a further reduction in force that impacts approximately 42% of the company's employees. Viracta ex
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place in New York City on Wednesday, September 11, 2024, at 8:30 a.m. EDT. A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Presentations" and archived for 90 days. About Viracta Therapeutics, Inc.Viracta is a clinical-stage precision o
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity and generally well-tolerated safety profile - - New positive data and productive feedback from the FDA support updated Nana-val clinical development plan in EBV-positive PTCL patients; randomized controlled trial planned to begin in the second half of 2025 to support potential registration - - Appointed Michael Faerm as Chief Financial Officer - SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology
- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial antitumor activity and generally well-tolerated safety profile - - Productive FDA meeting held to align on a potential regulatory path forward for Nana-val in patients with relapsed or refractory EBV-positive PTCL - - Updated Nana-val clinical development plan implemented to optimize its clinical benefit in EBV-positive PTCL patients and expedite a randomized controlled trial to support potential registration - - Viracta to host conference call and webcast on Wednesday, August 14 at 8:
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Michael Faerm as Viracta's new Chief Financial Officer, Viracta's Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta's 2021 Inducement Equity Incentive Plan. Additionally, Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. Each optio
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking. "We are delighted to welcome Mike, an accomplished life sciences industry & Wall Street veteran, who we believe will be instrumental in supporting our next phase of development," said Mark Rothera, President and Chief E
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) Initial results from the ongoing NAVAL-1 trial further validate Nana-val's "Kick and Kill" mechanism of action; additional data are expected in the third quarter of 2024 Plan to engage with U.S. Food and Drug Administration (FDA) in mid-2024 to align on requirements for accelerated approval and support speed to market strategy Progressed the Phase 1b/2 study of Nana-val in patients with advanced EBV+ solid tumors; on track to determine the recommended Phase 2 dose (RP2D) in the secon
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 11:00 a.m. EDT. A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" and archived for 90 days. About Viracta Therapeutics, Inc
– LENZ Therapeutics to debut on Nasdaq under the ticker symbol "LENZ" as a publicly traded company advancing late clinical-stage assets for the treatment of presbyopia – – Topline data from registration-enabling Phase 3 CLARITY trials for lead assets LNZ100 and LNZ101 expected in April 2024 – – Strong balance sheet with approximately $210 million of cash and cash equivalents, including $53.5 million from a concurrent PIPE financing – LENZ Therapeutics, Inc. (NASDAQ:LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced th
Leerink Partners downgraded Viracta Therapeutics from Outperform to Market Perform and set a new price target of $3.00 from $5.00 previously
RBC Capital Mkts initiated coverage of Viracta Therapeutics with a rating of Outperform and set a new price target of $10.00
HC Wainwright & Co. initiated coverage of Viracta Therapeutics with a rating of Buy and set a new price target of $35.00
SVB Leerink initiated coverage of Viracta Therapeutics with a rating of Outperform and set a new price target of $18.00
Evercore ISI initiated coverage of Viracta Therapeutics with a rating of Outperform and set a new price target of $45.00
- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial antitumor activity and generally well-tolerated safety profile - - Productive FDA meeting held to align on a potential regulatory path forward for Nana-val in patients with relapsed or refractory EBV-positive PTCL - - Updated Nana-val clinical development plan implemented to optimize its clinical benefit in EBV-positive PTCL patients and expedite a randomized controlled trial to support potential registration - - Viracta to host conference call and webcast on Wednesday, August 14 at 8:
– LENZ Therapeutics to debut on Nasdaq under the ticker symbol "LENZ" as a publicly traded company advancing late clinical-stage assets for the treatment of presbyopia – – Topline data from registration-enabling Phase 3 CLARITY trials for lead assets LNZ100 and LNZ101 expected in April 2024 – – Strong balance sheet with approximately $210 million of cash and cash equivalents, including $53.5 million from a concurrent PIPE financing – LENZ Therapeutics, Inc. (NASDAQ:LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced th
SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
SC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)
SC 13D/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
SC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)
SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Michael Faerm as Viracta's new Chief Financial Officer, Viracta's Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta's 2021 Inducement Equity Incentive Plan. Additionally, Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. Each optio
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking. "We are delighted to welcome Mike, an accomplished life sciences industry & Wall Street veteran, who we believe will be instrumental in supporting our next phase of development," said Mark Rothera, President and Chief E
SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Darrel P. Cohen, M.D., Ph.D. as Viracta's new Chief Medical Officer, the Compensation Committee of Viracta's Board of Directors granted Dr. Cohen a non-qualified stock option to purchase 235,000 shares of common stock under Viracta's 2021 Inducement Equity Incentive Plan. The option vests over four years, with 25% vesting on the one-year anniversary of Dr. Cohen's employment commencement date and the rem
Achieved efficacy threshold to advance Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma into Stage 2 becoming the leading indication in pivotal NAVAL-1 study of Nana-val Prioritized EBV+ diffuse large B-cell lymphoma and EBV+ post-transplant lymphoproliferative disease as key follow-on indications in NAVAL-1 trial Published Phase 1b/2 clinical trial data reporting promising durable signal of efficacy for Nana-val in patients with relapsed or refractory EBV+ lymphoma in Blood Advances, a Journal of the American Society of Hematology Completed enrollment into the fifth dose escalation level of the Phase 1b/2 study of Nana-val in advanced EBV+ solid tumors without any dose-limit
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer (CMO), effective immediately. Dr. Cohen brings more than 25 years of global clinical research and drug development experience, having contributed to the successful regulatory submissions of multiple novel oncology therapies including SUTENT® (sunitinib), XALKORI® (crizotinib), and IBRANCE® (palbociclib). Dr. Cohen will oversee the clinical development and regulatory advanceme
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced that, in connection with the appointment of Mark Rothera as Viracta's new President and Chief Executive Officer, the independent members of Viracta's Board of Directors approved the grant of a non-qualified stock option to Mr. Rothera to purchase 1,375,000 shares of common stock. The option vests over four years, with 25% vesting on the one-year anniversary of Mr. Rothera's employment commencement date and the remaining 75% vesting in equal monthly increments over the succeeding 36 months, subject to Mr. Rothera's cont
Viracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Officer Founding President and CEO Ivor Royston, M.D., will continue to serve as a Member of Viracta's Board of Directors SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced the succession of its President and Chief Executive Officer, Ivor Royston, M.D. to Mark Rothera, who was appointed as President and CEO and member of the Board of Directors, effective today. Dr. Royston will support the leadership transition and continue to serve as a member of the Board of Directors.
SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors. "Ms. Chung's unique combination of commercial and executive experience in oncology make her an ideal fit for Viracta's Board," said Roger J. Pomerantz, M.D., F.A.C.P., Chairman of the Board of Directors of Viracta. "She has an impressive record of building and leading teams supporting multi-billion-dollar oncology franchises, as well as a firm understanding of how to optimize drug launches. We expect her expertise to be invaluable as we
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is
SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointments of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, as independent members to Viracta's Board of Directors. "We are very pleased to welcome both Dr. Borellini and Dr. Barlow, two accomplished industry leaders with proven track records to the Viracta Board," said Roger J. Pomerantz, M.D., F.A.C.P., Chairman of the Board of Directors of Viracta. "Their collective experience in corporate strategy, oncology drug development and navigating the regulatory landscapes, in addition to their deep commercia
Gainers Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million. Purple Biotech (NASDAQ:PPBT) stock increased by 14.48% to $0.63. The market value of their outstanding shares is at $16.4 million. Akanda (NASDAQ:AKAN) stock rose 12.54% to $3.05. The market value of their outstanding shares is at $5.8 million. Viridian Therapeutics (NASDAQ:VRDN) shares rose 12.09% to $13.7. The market value of their outstanding shares is at $874.2 million. IGC Pharma (AMEX:IGC) shares increased by 11.21% to $0.48. The company's market cap stands at $36.1 million. OpGen (NASDAQ:OPGN) shares moved upwards by
Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target from $13 to $11.
Viracta Therapeutics (NASDAQ:VIRX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.35) by 34.29 percent.
Gainers Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $344.7 million. Syra Health (NASDAQ:SYRA) stock rose 14.96% to $1.14. The market value of their outstanding shares is at $7.4 million. Sage Therapeutics (NASDAQ:SAGE) shares increased by 13.12% to $14.65. The company's market cap stands at $880.5 million. Recursion Pharmaceuticals (NASDAQ:RXRX) shares moved upwards by 12.72% to $8.68. The market value of their outstanding shares is at $2.0 billion. Viracta Therapeutics (NASDAQ:VIRX) stock moved upwards by 12.05% to $0.95. The company's market cap stands at $37.3 million. BioVie (NASDAQ
Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 from $4.13 a year earlier. Travelers shares dipped 8.1% to $205.03 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers INVO Bioscience, Inc. (NASDAQ:INVO) shares shot up 256% to $2.78 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goa
Gainers INVO Bioscience (NASDAQ:INVO) stock rose 275.0% to $2.85 during Wednesday's regular session. The market value of their outstanding shares is at $7.4 million. As per the news, the Q4 earnings report came out yesterday. Vanda Pharma (NASDAQ:VNDA) stock moved upwards by 33.33% to $5.4. The company's market cap stands at $310.7 million. Galera Therapeutics (NASDAQ:GRTX) shares rose 27.76% to $0.22. The company's market cap stands at $11.8 million. SINTX Techs (NASDAQ:SINT) shares increased by 27.51% to $0.03. The company's market cap stands at $3.5 million. Viracta Therapeutics (NASDAQ:VIRX) stock moved upwards by 27.51% to $0.91. The company's market cap stands at $35.7 million. R
Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $13 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Buy and maintains $4 price target.